While BioNTech SE ADR has underperformed by -1.67%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, BNTX fell by -13.93%, with highs and lows ranging from $129.27 to $81.20, whereas the simple moving average fell by -8.75% in the last 200 days.
On June 05, 2025, H.C. Wainwright Reiterated BioNTech SE ADR (NASDAQ: BNTX) to Buy. A report published by Goldman on May 29, 2025, Initiated its previous ‘Neutral’ rating for BNTX. Citigroup also rated BNTX shares as ‘Buy’, setting a target price of $145 on the company’s shares in an initiating report dated March 13, 2025. Truist Initiated an Buy rating on January 10, 2025, and assigned a price target of $172. Wells Fargo initiated its ‘Overweight’ rating for BNTX, as published in its report on December 11, 2024. Evercore ISI also rated the stock as ‘Outperform’.
Analysis of BioNTech SE ADR (BNTX)
Further, the quarter-over-quarter increase in sales is 113.52%, showing a positive trend in the upcoming months.
To gain a thorough understanding of BioNTech SE ADR’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -1.81% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 8.48, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and BNTX is recording an average volume of 865.85K. On a monthly basis, the volatility of the stock is set at 3.57%, whereas on a weekly basis, it is put at 2.10%, with a gain of 1.84% over the past seven days. Furthermore, long-term investors anticipate a median target price of $141.67, showing growth from the present price of $98.08, which can serve as yet another indication of whether BNTX is worth investing in or should be passed over.
How Do You Analyze BioNTech SE ADR Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 1.52%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 21.94% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
